Xponance Inc. Acquires 4,139 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Xponance Inc. boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 22.0% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 22,978 shares of the company's stock after acquiring an additional 4,139 shares during the period. Xponance Inc.'s holdings in IDEXX Laboratories were worth $9,500,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the stock. Empowered Funds LLC boosted its stake in IDEXX Laboratories by 2.8% during the third quarter. Empowered Funds LLC now owns 1,310 shares of the company's stock worth $662,000 after buying an additional 36 shares during the period. Natixis Advisors LLC lifted its stake in IDEXX Laboratories by 8.0% in the third quarter. Natixis Advisors LLC now owns 43,174 shares of the company's stock worth $21,812,000 after acquiring an additional 3,206 shares during the last quarter. Mutual of America Capital Management LLC lifted its stake in IDEXX Laboratories by 0.6% in the third quarter. Mutual of America Capital Management LLC now owns 11,240 shares of the company's stock worth $5,679,000 after acquiring an additional 68 shares during the last quarter. Thrivent Financial for Lutherans raised its holdings in IDEXX Laboratories by 150.6% during the third quarter. Thrivent Financial for Lutherans now owns 108,258 shares of the company's stock worth $54,693,000 after purchasing an additional 65,050 shares in the last quarter. Finally, Quest Partners LLC raised its holdings in IDEXX Laboratories by 4,059.4% during the third quarter. Quest Partners LLC now owns 2,870 shares of the company's stock worth $1,450,000 after purchasing an additional 2,801 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analysts Forecast Growth

IDXX has been the topic of a number of analyst reports. Leerink Partners started coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price objective on the stock. Barclays increased their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. StockNews.com downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday, March 15th. Finally, Bank of America increased their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and a consensus price target of $533.75.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.11% of the company's stock.

IDEXX Laboratories Trading Up 0.1 %

NASDAQ IDXX traded up $0.37 on Friday, hitting $420.99. 706,610 shares of the company were exchanged, compared to its average volume of 552,075. The company's 50 day moving average price is $437.36 and its 200-day moving average price is $444.94. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The firm has a market capitalization of $34.12 billion, a P/E ratio of 39.46, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $548.88.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.